Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells

c-Met Overexpression Contributes to the Acquired Apoptotic Resistance of Nonadherent Ovarian Cancer Cells through a Cross Talk Mediated by Phosphatidylinositol 3-Kinase and Extracellular Signal-Regulated Kinase 1/2

(2015) Maggie K.S. Tang et al.   NEOPLASIA

Two 4N Cell-Cycle Arrests Contribute to Cisplatin-Resistance

(2013) Hong Shen et al.   PLoS One

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

(2012) Asao Sakai et al.   Journal of Thoracic Oncology

Genome-wide copy number variation (CNV) in patients with autoimmune Addison's disease

(2011) Ingeborg Brønstad et al.   BMC Medical Genetics

Treatment options for small cell lung cancer – do we have more choice?

(2010) M Puglisi et al.   BRITISH JOURNAL OF CANCER

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Chromosomal instability: A composite phenotype that influences sensitivity to chemotherapy

(2010) Sarah E. McClelland et al.   CELL CYCLE

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

(2009) Hiroaki Ozasa et al.   CANCER SCIENCE

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Rad51 Down-Regulation and Extracellular Signal-Regulated Kinases 1 and 2 Inactivation in Emodin and Mitomycin C-Induced Synergistic Cytotoxicity in Human Non-Small-Cell Lung Cancer Cells

(2009) Y.-J. Su et al.   MOLECULAR PHARMACOLOGY

Optimized Quantification of Fragmented, Free Circulating DNA in Human Blood Plasma Using a Calibrated Duplex Real-Time PCR

(2009) Martin Horlitz et al.   PLoS One

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

(2008) L. Toschi et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

(2008) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY

Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: Fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients

(2008) Chang-Min Choi et al.   LUNG CANCER

MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer

(2008) T. Oguri et al.   MOLECULAR CANCER THERAPEUTICS

HGF Increases Cisplatin Resistance via Down-Regulation of AIF in Lung Cancer Cells

(2007) Jin-Tang Chen et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY